Unknown

Dataset Information

0

Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.


ABSTRACT: Chemotherapy is a powerful cancer treatment but suffers from poor biocompatibility and a lack of tumor targeting. Here, we developed a CD44-targeted polymeric nanocomplex by encapsulating 10-hydroxycamptothecin (HCPT) into hyaluronic acid nanoparticles (HANP) for targeted cancer therapy. In vitro, the HANP/HCPT showed improved cytotoxicity to five cancer cell lines including HT29, A549, MDA-MB-231, HepG2, and MDA-MB-435 versus free HCPT. After systemic administration into MDA-MB-231 breast cancer xenograft, tumor growth was significantly inhibited 5.25 ± 0.21 times in the HANP/HCPT treated group relative to the nontreated group. In addition, the treatment response was also accessed and confirmed by 18F-fluoro-2-deoxy-D-glucose ([18F] FDG) positron emission tomography (PET). The MDA-MB-231 tumors responded to HANP/HCPT 7 days after the first treatment, which benefits treatment strategy adjustment and personalization. No apparent systemic toxic effects were seen in mice treated with HANP/HCPT. In summary, the HANPs have great promise as a targeted drug carrier for cancer chemotherapy. Our HANP platform can also deliver other hydrophobic chemotherapy agents.

PROVIDER: S-EPMC5612705 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8001650 | BioStudies
| S-EPMC5750524 | BioStudies
| S-EPMC7960738 | BioStudies
| S-EPMC6785558 | BioStudies
| S-EPMC7177700 | BioStudies
| S-EPMC6397149 | BioStudies
2022-02-16 | PXD028806 | Pride
| S-EPMC5933713 | BioStudies
| S-EPMC3738633 | BioStudies
| S-EPMC6944726 | BioStudies